Ashley E. Davis is a lead principal at West Front Strategies, a multi-million dollar lobbying firm she co-founded in 2015. A co-founder of the firm she oversees advocacy efforts for the interests of her Fortune 500 clients before the legislative and executive branches of the U.S. government. Clients span a wide variety of industries, including Microsoft, Adobe, Mylan, AETNA, Expedia, Walgreen Co. and Prudential Financial, Inc.
Ashley’s expertise comes from years working in the Executive Branch, where she served in a number of leadership roles. As Special Assistant to National Director (and then Secretary) of Homeland Security Tom Ridge, Ashley directed the daily operations and oversaw the staff at the newly created Office of Homeland Security. Prior to serving as Special Assistant, Ashley was a member of the task force that created the Department of Homeland Security and was involved in creating several government programs, including USA Freedom Corp and several classified programs.
Following her tenure at the White House, Ashley served as a managing principal at Blank Rome and managed the law firm’s strategic alliances with over 20 international public affairs firms.
Ashley holds a Masters of International Business from McDonough School of Business,
Georgetown University and an undergraduate degree from Westminster College, where she is a Member of the Board of Trustees. She sits on several non-profit and corporate Boards such as Turning Point Brands Inc., Vital Voices Global Partnership, the Women’s Democracy Network at the International Republican Institute, the Board of Trustees at Westminster College, Kennedy Center National Symphony Orchestra and the National Museum of Women in the Arts and is a member of Women Corporate Directors.
Agenda: Day 1 Oct 6, 2020
Agenda: Day 2 Oct 7, 2020
Fireside Chat: U.S. UPDATE
What a Democrat Administration & Congress has in Store for U.S. Drug Pricing
Can President Biden do what Donald Trump and Barack Obama tried to do but failed? Examine the latest rumours swirling around Washington, D.C., regarding ‘forced’ lower drug payments by Medicare and other proposed action. Assess how the following could potentially impact Canadian companies:
- The passing of H.R. 3, which allows Medicare to negotiate lower prices for prescription drugs and set a $2,000 maximum for out-of-pocket spending
- The establishment of a health research agency
- A Republican backlash leading up to the 2022 midterm elections
Get answers to important questions that you won’t find in traditional media sources.